Gimoti denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gimoti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Gimoti on Medical-Necessity Grounds

Gimoti (metoclopramide nasal spray) is an FDA-approved treatment for diabetic gastroparesis. BCBS medical-necessity denials for this drug typically occur when the plan's reviewers conclude that the submitted documentation does not clearly establish the diagnosis, the severity of symptoms, or why an alternative delivery form is required for this specific patient. Because gastroparesis management is highly individualized, a generic chart note often fails to address the precise clinical criteria the plan uses to evaluate this request.

## Why This Denial Is Appealable

FDA approval and published clinical guidelines from recognized gastroenterology organizations support Gimoti as a treatment option for appropriate gastroparesis patients. If your prescriber determined that this formulation is medically necessary — for instance, because nausea or vomiting impairs reliable absorption of an oral agent — that clinical rationale is the heart of your appeal. Insurers must evaluate medical necessity based on individual clinical circumstances, not solely on whether a cheaper alternative exists.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (job-based plans) or applicable state law. Submit within the timeframe shown on your denial letter (commonly 180 days).
• External review: Under ACA §2719, you may request an independent external review after exhausting internal appeals — or simultaneously if your plan allows. The external reviewer is a neutral, accredited organization not employed by the plan. Most external review decisions arrive within 45 days of a standard request, or as few as 72 hours on an expedited basis if your condition is urgent.
• Expedited option: If a standard timeline would seriously jeopardize your health, request expedited review explicitly in writing.

## Documentation to Gather

• Diagnosis confirmation: Gastric-emptying study or equivalent diagnostic record, with the interpreting physician's name and date.
• Prior-treatment history: Names, dates, doses, and documented outcomes or intolerances for all previously tried agents — especially oral metoclopramide and any other prescribed therapies.
• Clinical severity: Chart notes documenting symptom burden (nausea, vomiting frequency, weight impact, functional status).
• Medical-necessity letter: A signed letter from your prescriber explaining, in clinical terms, why Gimoti's nasal-spray delivery is specifically required for you — referencing the FDA-approved prescribing information and the applicable gastroparesis guideline from a recognized professional society.

## Criteria-Mapping Structure

Obtain a full copy of BCBS's current Gimoti coverage policy (request it from member services or look for it under "Medical Policies" on the plan's website). Then build a table:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Confirmed diagnosis of diabetic gastroparesis | [gastric-emptying study date + result] | | Trial and inadequate response to [listed prior therapies] | [prescription records + chart notes with dates and outcomes] | | Clinical rationale for nasal-spray formulation | [prescriber letter citing FDA label rationale] | | Prescriber specialty or attestation | [prescriber credentials] |

Match every stated requirement with a specific, dated document. Gaps in documentation — not gaps in medical appropriateness — are the most common reason internal appeals fail.